

# First-line tagraxofusp leads to durable responses and prolonged survival in adults with blastic plasmacytoid dendritic cell neoplasm regardless of fitness level

Blastic plasmacytoid dendritic cell neoplasm (BPDCN), an aggressive, orphan hematologic neoplasm that expresses CD123 and other markers, presents primarily in skin, bone marrow, and blood.<sup>1</sup> While BPDCN impacts all ages, the median age of adults with BPDCN is 67 years.<sup>2</sup> The goal of first-line induction therapy is to attain a durable remission with limited side effects. For eligible patients who successfully achieve a rapid and durable complete response (CR) without cumulative non-hematologic or hematologic toxicities, hematopoietic cell transplantation (HCT) offers a potentially curative option.<sup>1</sup>

The first-in-class CD123-directed agent tagraxofusp is the only approved treatment for BPDCN,<sup>3,4</sup> with a well-characterized and manageable safety profile without cumulative myelosuppression. Regulatory approvals were based on results from a prospective, multicenter phase II study (*clinicaltrials.gov. Identifier: NCT02113982*) that employed prespecified, multisystem response criteria and endpoints.<sup>5,6</sup> In this pivotal study,<sup>5,6</sup> the overall response rate (ORR) was 75% in 65 first-line patients (median age 68 years) treated with tagraxofusp (12 µg/kg once daily during the first 5 days of a 21-day cycle). Moreover, 57% achieved a complete response (CR) or clinical CR (CRc: CR with residual skin abnormalities not indicative of active disease) with a median duration of 24.9 months. Half (51%) of these patients were successfully bridged to HCT and reached a median overall survival (OS) of 38.4 months.<sup>6</sup> Real-world data confirm these results.<sup>7</sup>

While not approved for BPDCN, intensive multi-agent chemotherapy (IC) prior to HCT has been used, despite short- and long-term toxicities, including myelosuppression, and short duration of response (DOR). Because of age and comorbidities, many patients with BPDCN are ineligible for IC prior to consideration for HCT, and use is restricted to young/fit patients.<sup>8</sup> Overall, these patients from all age groups could benefit from a safe and effective targeted first-line treatment with tagraxofusp to achieve rapid and durable CR to increase HCT eligibility, without risk of long-term toxicities.

Given the heterogeneity in patient fitness, an important clinical question is whether baseline fitness affects tagraxofusp treatment outcomes and safety. The HCT-specific comorbidity index (HCT-CI), a risk-stratification model developed to predict overall and non-relapse mortality after allogeneic-HCT, has been well validated in various hematologic malignancies and is useful for assessing fitness/frailty level.<sup>9-11</sup> HCT-CI includes categories of comorbidities/organ

dysfunction assigned a weight of 0 (low-risk), 1-2 (intermediate-risk), or  $\geq 3$  (high-risk) based on a patient's past medical history or abnormal laboratory values immediately prior to conditioning treatment. We, therefore, utilized the HCT-CI<sup>12</sup> in a *post hoc* analysis of the pivotal trial to assess tagraxofusp safety and efficacy across different baseline fitness levels.

Study methods and results have been previously published.<sup>5,6</sup> The study was approved by the institutional review board at each participating center and conducted in accordance with the principles of the Declaration of Helsinki and applicable clinical practice guidelines. All study participants provided written informed consent. This *post hoc* analysis categorized 65 treatment-naïve patients based on available medical history, concomitant medications, and laboratory values into previously validated HCT-CI low-risk (HCT-CI 0), intermediate-risk (HCT-CI 1-2), or high-risk (HCT-CI  $\geq 3$ ) groups.<sup>9-11</sup> Efficacy and safety data for each HCT-CI risk group were analyzed by descriptive statistics only.

Of the 65 patients analyzed, 15 (23%) patients had a low-risk score, 22 (34%) an intermediate-risk score, and 28 (43%) a high-risk score (Table 1). Prevalence of the HCT-CI comorbidities is shown in *Online Supplementary Table S1*. The proportion of patients with a normal Eastern Cooperative Oncology Group performance status decreased with increasing HCT-CI risk score (67%, 50% and 36%, respectively).

The median duration of follow-up was 27.7 months (range, 2.6-51.7) for the low-risk group, 36.6 months (range, 0.2-58.1) for intermediate-risk, and 36.3 months (range, 3.9-54.0) for high-risk. The three groups had a similar median duration of exposure: 72 days (range, 37-545) for low-risk, 71 days (range, 2-159) for intermediate-risk, and 68 days (range, 1-1,622) for high-risk. Patients in all groups started a median of four cycles and, in cycle 1, received a median of four doses for low-risk, five doses for intermediate-risk, and four doses for high-risk. Reasons for study discontinuation are shown in *Online Supplementary Table S2*.

The ORR was high in all groups: 80% (low-risk), 68% (intermediate-risk), and 79% (high-risk) (Figure 1A). Median time to response was rapid and similar: 24 days (range, 20-49) for low-risk, 22 days (range, 14-53) for intermediate-risk, and 25 days (range, 14-97) for high-risk. Median time to CR was numerically longer in the low-risk (45 days; range, 20-131) and high-risk (43 days; range, 22-107) groups than in the intermediate-risk group (24 days; range, 14-53). The median DOR was numerically longer in the low- (24.9

months; range, 1.0-51.1) and intermediate-risk (not reached [NR]; range, 0.9-57.4 months) groups than in the high-risk group (3.9 months; range, 0.7-52.3).

Twenty-one patients were bridged to HCT (5 low-risk, 10 intermediate-risk, 6 high-risk). The three groups of bridged patients had received a median of four cycles from start of tagraxofusp to HCT, and had a similar median time from diagnosis to HCT and a similar median time from the first dose of tagraxofusp to HCT (*Online Supplementary Table S3*). Pre-transplant CR/CRc rates were high in all three risk groups (100% low-risk, 90% intermediate-risk, 83% high-risk; Figure 1B). Transplanted patients in the low- and intermediate-risk groups had numerically shorter median times to overall response (21 days, range, 20-49; and 23 days, range, 14-53, respectively) than patients in the high-risk group (41 days, range, 23-57). The median DOR for transplanted patients was NR in any group.

The median OS in the overall population was 38.4 months (95% confidence interval [CI]: 8.6-not estimable [NE]) in the low-risk group, 15.8 months (95% CI: 9.0-NE) in the intermediate-risk group, and 11.8 months (95% CI: 6.2-18.9) in the high-risk group (Figure 1C). Notably, in the trans-

planted population, median OS was 38.4 months (95% CI: 27.7-NE) in the low-risk group and NR (95% CI: 3.4-NE and 95% CI: 4.1-NE) in both intermediate- and high-risk groups (Figure 1D).

The safety profile of tagraxofusp was consistent across HCT-CI risk groups and with the overall trial population. Table 2 summarizes treatment-emergent adverse events (AE) leading to dose reduction, dose interruption, and the most common hematologic and non-hematologic any-grade treatment-related AE (TRAE). Most hematologic and non-hematologic TRAE occurred during cycle 1 and were transient. Grade 3-4 TRAE occurred in 60% (low-risk), 46% (intermediate-risk), and 64% (high-risk) of patients. Common grade 3-4 TRAE included increased alanine/aspartate aminotransferase (40%, 14%, and 29%, respectively) and, to a lesser extent, thrombocytopenia (33%, 14%, and 14%, respectively) and neutropenia (7%, 5%, and 11%, respectively). Capillary leak syndrome (CLS) was observed in 7% (low-risk), 23% (intermediate-risk), and 21% (high-risk) of patients. CLS events were predominantly grade 1-2, occurred in cycle 1, and resolved at a median of 4-6 days across all risk groups (*Online Supplementary Table S4*). Deaths due

**Table 1.** Baseline characteristics by hematopoietic cell transplantation-comorbidity index risk groups of all patients treated with first-line tagraxofusp.


Characteristics	Low risk N=15	Intermediate risk N=22	High risk N=28
Age, years, median (range)	61 (22-79)	68 (22-84)	70 (23-84)
Sex, N (%)			
Male	14 (93)	14 (64)	24 (86)
Race, N (%)			
American Indian or Alaska Native	1 (7)	0	0
Asian	0	2 (9)	0
Black or African American	2 (13)	0	0
White	11 (73)	19 (86)	27 (96)
Other	1 (7)	1 (5)	1 (4)
Ethnicity, N (%)			
Not Hispanic or Latino	13 (87)	20 (91)	26 (93)
ECOG performance status, N (%)			
0	10 (67)	11 (50)	10 (36)
1	4 (27)	11 (50)	16 (57)
2	0	0	2 (7)
Missing	1 (7)	0	0
BMI, kg/m <sup>2</sup> , median (range)	28 (23-35)	29 (22-48)	31 (21-40)
Time since BPDCN diagnosis, months, median (range)	1.4 (0-2.9)	1.1 (0-4.8)	0.9 (0-3.2)
Disease involvement at baseline, N (%)			
Bone marrow	5 (33)	6 (27)	21 (75)
Lymph node	7 (47)	8 (36)	18 (64)
Peripheral blood	2 (13)	3 (14)	12 (43)
Skin	13 (87)	22 (100)	25 (89)
Visceral	3 (20)	0	6 (21)
≥2 disease sites	9 (60)	11 (50)	25 (89)
≥5% bone marrow blasts	6 (40)	6 (27)	21 (75)

BMI: body mass index; BPDCN: blastic plasmacytoid dendritic cell neoplasm; ECOG: Eastern Cooperative Oncology Group.

to TRAE were two (9%) patients with CLS and one (5%) patient with myocardial infarction in the intermediate-risk group. There were no deaths due to TRAE in the low-risk or high-risk groups.

This analysis represents the first reported use of a pre-treatment HCT-CI score to evaluate treatment outcomes in patients with BPDCN, demonstrating how tagraxofusp performs across varying levels of comorbidities and (che-

motherapy) fitness. Tagraxofusp demonstrated uniformly high response rates irrespective of HCT-CI fitness risk level, with an 80% ORR for low-risk, 68% for intermediate-risk, and 79% for high-risk groups. Responses were durable, and importantly, patients across all fitness groups successfully bridged to transplant. Overall, OS was prolonged in the transplanted population, with median OS NR in intermediate- and high-risk patients bridged to HCT. Tagraxofusp's



**Figure 1. Efficacy outcomes by hematopoietic cell transplantation-comorbidity index risk groups.** (A) Objective responses in all patients.<sup>a</sup> (B) Objective responses in patients bridged to transplant. (C) Kaplan-Meier overall survival (OS) curves in all patients. (D) Kaplan-Meier OS curves in patients bridged to transplant. BPDCN: blastic plasmacytoid dendritic cell neoplasm; CI: comorbidity index; CR: complete response; CRc: CR with residual skin abnormalities not indicative of active BPDCN; HCT: hematopoietic cell transplantation; NE: not estimable; NR: not reached; ORR: objective response rate; PR: partial response. <sup>a</sup>Four patients in the intermediate-risk group were not evaluable; mo: months;

**Table 2.** Adverse events in four or more patients in any hematopoietic cell transplantation-comorbidity index risk group treated with first-line tagraxofusp.

Any-grade AE, N (%)	Low risk N=15	Intermediate risk N=22	High risk N=28
Any TEAE leading to dose reduction	1 (7)	0	1 (4)
Any TEAE leading to dose interruption	13 (87)	15 (68)	19 (68)
TEAE leading to dose interruption			
ALT increased	5 (33)	1 (5)	4 (14)
AST increased	5 (33)	1 (5)	5 (18)
Hypoalbuminemia	3 (20)	3 (14)	5 (18)
Pyrexia	1 (7)	4 (18)	2 (7)
Weight increased	5 (33)	9 (41)	6 (21)
Hematologic TRAE			
Anemia	0	5 (23)	4 (14)
Neutropenia	1 (7)	2 (9)	4 (14)
Thrombocytopenia	7 (47)	6 (27)	7 (25)
Non-hematologic TRAE			
ALT increased	10 (67)	10 (46)	14 (50)
AST increased	9 (60)	9 (41)	15 (54)
Back pain	1 (7)	1 (5)	4 (14)
Chills	6 (40)	3 (14)	2 (7)
CLS	1 (7)	5 (23)	6 (21)
Decreased appetite	1 (7)	1 (5)	4 (14)
Fatigue	2 (13)	5 (23)	4 (14)
Hypoalbuminemia	4 (27)	10 (46)	11 (39)
Hypotension	2 (13)	4 (18)	6 (21)
Nausea	5 (33)	3 (14)	7 (25)
Peripheral edema	0	3 (14)	5 (18)
Pyrexia	6 (40)	6 (27)	6 (21)
Tachycardia	3 (20)	0	2 (7)
Vision blurred	3 (20)	0	0
Weight increased	3 (20)	6 (27)	9 (32)

AE: adverse event; ALT: alanine aminotransferase; AST: aspartate aminotransferase; CLS: capillary leak syndrome; TEAE: treatment-emergent adverse event; TRAE: treatment-related adverse event.

safety profile remained consistent across all HCT-CI risk groups, mirroring previously reported data for the overall population.<sup>5,6</sup>

The HCT-CI, specifically developed and validated for patients undergoing HCT for hematologic malignancies, offers superior sensitivity and predictive accuracy over more general comorbidity indices (e.g., Charlson Comorbidity Index), by incorporating transplant-relevant comorbidities.<sup>12</sup> Unlike with IC where high-risk HCT-CI subgroups in acute myeloid leukemia have shown significant early mortality (29% within 28 days),<sup>13</sup> thus limiting treatment options, the current analysis establishes tagraxofusp as a safe and efficacious treatment for BPDCN across all HCT-CI subgroups. While acknowledging the *post hoc* nature of this analysis, the patient population's distribution across low-, intermediate-, and high-risk HCT-CI categories (23%, 34%, and 43% respectively) closely aligns with a large BPDCN cohort from the Center for International Blood and Marrow Transplant registry (26%, 31%, and 42% respectively).<sup>14</sup> This robust comparability strengthens the validity of our stratification methodology. Notably, the high-risk group included older

patients who had more BPDCN organ involvement, which aligns with previous reports showing number of comorbidities and BPDCN disease sites are associated with older age.<sup>15</sup> Similarly, the distribution of patients with  $\geq 5\%$  bone marrow blasts at baseline was highest in the high-risk group. In conclusion, results from this *post hoc* analysis show that tagraxofusp induced durable responses without the prolonged myelosuppression and cumulative toxicities associated with IC. Critically, tagraxofusp also enabled bridging to HCT for eligible patients across the entire spectrum of fitness, including those high-risk individuals potentially deemed ineligible for intensive cytotoxic upfront regimens. These results affirm tagraxofusp as the standard of care first-line treatment for all eligible patients with BPDCN irrespective of baseline fitness level.

## Authors

Naveen Pemmaraju,<sup>1</sup> Marco Herling,<sup>2</sup> Kendra L. Sweet,<sup>3</sup> Anthony S. Stein,<sup>4</sup> Sumithira Vasu,<sup>5</sup> Todd L. Rosenblat,<sup>6</sup> David A. Rizzieri,<sup>7</sup> Cristina

Papayannidis,<sup>8</sup> Eunice S. Wang,<sup>9</sup> Marina Konopleva,<sup>10</sup> Michael Zuurman,<sup>11</sup> Alessandra Tosolini,<sup>12</sup> Muzaffar Qazilbash<sup>1</sup> and Andrew A. Lane<sup>13</sup>

<sup>1</sup>The University of Texas MD Anderson Cancer Center, Houston, TX, USA; <sup>2</sup>University Hospital Leipzig and Cancer Center Central Germany (CCCG) Leipzig-Jena, Germany; <sup>3</sup>Moffitt Cancer Center, Tampa, FL, USA; <sup>4</sup>City of Hope, Duarte, CA, USA; <sup>5</sup>The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA; <sup>6</sup>Columbia University Herbert Irving Comprehensive Cancer Center, New York, NY, USA; <sup>7</sup>Novant Health Cancer Institute, Charlotte, NC, USA; <sup>8</sup>IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia “Seràgnoli”, Bologna, Italy; <sup>9</sup>Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA; <sup>10</sup>Albert Einstein College of Medicine/Montefiore Cancer Center, Bronx, NY, USA; <sup>11</sup>Menarini Group, Machelen, Belgium; <sup>12</sup>Menarini Group, New York, NY, USA and <sup>13</sup>Dana-Farber Cancer Institute, Boston, MA, USA

Correspondence:

N. PEMMARAJU - npemmaraju@mdanderson.org

<https://doi.org/10.3324/haematol.2025.300036>

Received: October 10, 2025.

Accepted: December 31, 2025.

Early view: January 15, 2026.

Published under a CC BY license 

### Disclosures

NP discloses institutional research grant from NIH/NCI, US Department of Defense; consultant/scientific advisor board/ speaking for AbbVie, Aplastic Anemia & MDS International Foundation, Aptitude Health, Astellas Pharma US, Blueprint Medicines, Bristol Myers Squibb Pharmaceuticals, CancerNet, CareDx, Celgene, Cimeio Therapeutics AG, ClearView Healthcare Partners, CTI BioPharma, Curio Science, Dava Oncology, EUSA Pharma, Harborside Press, Imedex, Immunogen, Intellisphere, Karyopharm, Magdalen Medical Publishing, Medscape, Menarini Group, Morphosys, Neopharm, Novartis Pharmaceuticals, OncLive, Pacylex, Patient Power, PeerView Institute for Medical Education, Pharma Essentia, and Physician Education Resource (PER); board of directors/management for Dan’s House of Hope; leadership with ASH committee on communications, ASCO Cancer.Net editorial board; licenses with Karger Publishers; editorial board (unpaid) for HemOnc Times/Oncology Times. MH discloses research funding from BeiGene and JanPix; consulting or advisory role for BeiGene, Janssen, Stemline Menarini and Takeda; honoraria from BeiGene, Janssen, Roche, Stemline Menarini and Takeda; expert testimony for Stemline Menarini; travel accommodations/expenses from BeiGene and Janssen. KLS discloses institutional research funding from Incyte and Jazz; advisory/consultant role for JazzBri, Nkarta and Novartis; honoraria from Bristol Myers Squibb; expert testimony with Nelson Mullins; travel accommodations/expenses from Bristol Myers Squibb and Jazz; participation on a DSMB or advisory board for

Karyopharm; stock or stock options with BeiGene. ASS discloses honoraria from Amgen, Syndex Bio and Debio Pharma; consultant for Debio Pharma and Syndex Bio. SV discloses institutional research funding from Sanofi; participation on a data safety monitoring board or advisory board for Alexion. TLR has no conflicts of interest to disclose. DAR discloses data safety monitoring board or advisory board for Cellectis. CP discloses consulting/advisory role and participation on a data safety monitoring board or advisory board for AbbVie, Astellas, Blueprint, Delbert Laboratories, GSK, ImCheck, Istituto Gentili, Janssen, Jazz Pharmaceuticals and Pfizer; honoraria from AbbVie, Amgen, Astellas, Bristol Myers Squibb, Incyte, Janssen, Menarini/Stemline, Novartis, Pfizer and Servier. ESW discloses advisory/consulting for AbbVie, Blueprint, Daiichi Sankyo, Immunogen, Kite, Kura, Novartis, Qiagen, Rigel, Ryvu, Schrodinger, Servier, Stemline, Syndax and Takeda; speaking for Pfizer, Astellas and Dava; data safety monitoring board for Gilead and AbbVie; section editor for UpToDate. MK discloses institutional research funding from AbbVie, Janssen and Klondike Biopharma; consulting/ advisory role for AbbVie, Adaptive, AmMax, Curis, Janssen, Kyowa Kirin, Menarini/Stemline Therapeutics, Novartis, Sanofi Aventis, Servier and Vincerx; participation on a data safety monitoring board or advisory board for AbbVie, Auxenion GmbH, Dark Blue Therapeutics, Legend, MEI Pharma, Menarini/Stemline Therapeutics, Novartis and Syndax. MZ and AT disclose employment with Menarini Group. MQ discloses research funding from Angiocrine, Janssen and Sanofi; consulting/advisory role for Sanofi; participation on a data safety monitoring board or advisory board for Autolus. AAL discloses institutional research funding from AbbVie and Stemline Therapeutics; consulting or advisory role for Cimeio Therapeutics, IDRx, Jnana Therapeutics, ProteinQure, Qiagen and Stelexis BioSciences; steering committee for Stemline Therapeutics; stock or stock options with Medzown and Stelexis BioSciences.

### Contributions

NP, MH, and MZ contributed to the conception and design of this *ad hoc* analysis. All authors acquired the data. All authors analyzed the data; and all authors contributed to data interpretation, manuscript writing, editing, and content review, and approved the final draft of the manuscript.

### Acknowledgments

We thank the patients and their families, and the investigators, co-investigators, and their participating institutions. Medical writing and editing assistance was provided by Monica Nicosia and Claire Gilmore of Phillips Group Oncology Communications, Inc., and funded by the Menarini Group.

### Funding

This study was funded by the Menarini Group.

### Data-sharing statement

The data that support the results of this study may be requested for products and the relevant indications that have been authorized by the regulatory authorities in Europe/the United States (or, if not, 2 years have elapsed since the study completion). The Menarini Group

will review requests individually to determine whether (i) the requests are legitimate and relevant and meet sound scientific research principles, (ii) the requests are within the scope of the participants' informed consent, and (iii) the request is compliant with any applicable law and regulation and with any contractual relationship that Menarini Group and its affiliates and partners have in place with

respect to the study and/or the relevant product. Prior to making data available, requestors will be required to agree in writing to certain obligations, including without limitation, compliance with applicable privacy and other laws and regulations. Proposals should be directed to [medicalinformation@menarinistemline.com](mailto:medicalinformation@menarinistemline.com).

## References

---

1. Jain A, Sweet K. Blastic plasmacytoid dendritic cell neoplasm. *J Natl Compr Canc Netw*. 2023;21(5):515-521.
2. Laribi K, Baugier de Materre A, Sobh M, et al. Blastic plasmacytoid dendritic cell neoplasms: results of an international survey on 398 adult patients. *Blood Adv*. 2020;4(19):4838-4848.
3. Elzonris (tagraxofusp-erzs) injection [prescribing information]. 2023. Available at [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2023/761116s009lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761116s009lbl.pdf). Accessed May 27, 2025.
4. Elzonris [summary of product characteristics]. 2021. Available at [https://www.ema.europa.eu/en/documents/product-information/elzonris-epar-product-information\\_en.pdf](https://www.ema.europa.eu/en/documents/product-information/elzonris-epar-product-information_en.pdf). Accessed May 27, 2025.
5. Pemmaraju N, Lane AA, Sweet KL, et al. Tagraxofusp in blastic plasmacytoid dendritic-cell neoplasm. *N Engl J Med*. 2019;380(17):1628-1637.
6. Pemmaraju N, Sweet KL, Stein AS, et al. Long-term benefits of tagraxofusp for patients with blastic plasmacytoid dendritic cell neoplasm. *J Clin Oncol*. 2022;40(26):3032-3036.
7. Herling M, Angelucci E, Benoit TM, et al. Durable outcomes with manageable safety leading to prolonged survival with tagraxofusp for treatment-naïve patients with blastic plasmacytoid dendritic cell neoplasm: real world results from a European Named Patient Program. *Ann Hematol*. 2025;104(8):4121-4131.
8. Pemmaraju N, Deconinck E, Mehta P, et al. Recent advances in the biology and CD123-directed treatment of blastic plasmacytoid dendritic cell neoplasm. *Clin Lymphoma Myeloma Leuk*. 2024;24(4):e130-e137.
9. Sorror ML, Sandmaier BM, Storer BE, et al. Comorbidity and disease status based risk stratification of outcomes among patients with acute myeloid leukemia or myelodysplasia receiving allogeneic hematopoietic cell transplantation. *J Clin Oncol*. 2007;25(27):4246-4254.
10. Farina L, Bruno B, Patriarca F, et al. The hematopoietic cell transplantation comorbidity index (HCT-CI) predicts clinical outcomes in lymphoma and myeloma patients after reduced-intensity or non-myeloablative allogeneic stem cell transplantation. *Leukemia*. 2009;23(6):1131-1138.
11. Barba P, Ratan R, Cho C, et al. Hematopoietic cell transplantation comorbidity index predicts outcomes in patients with acute myeloid leukemia and myelodysplastic syndromes receiving CD34(+) selected grafts for allogeneic hematopoietic cell transplantation. *Biol Blood Marrow Transplant*. 2017;23(1):67-74.
12. Sorror ML, Maris MB, Storb R, et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. *Blood*. 2005;106(8):2912-2919.
13. Giles FJ, Borthakur G, Ravandi F, et al. The haematopoietic cell transplantation comorbidity index score is predictive of early death and survival in patients over 60 years of age receiving induction therapy for acute myeloid leukaemia. *Br J Haematol*. 2007;136(4):624-627.
14. Murthy HS, Zhang MJ, Chen K, et al. Allogeneic hematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: a CIBMTR analysis. *Blood Adv*. 2023;7(22):7007-7016.
15. Lin X, Wang L, Hu Q, et al. Incidence, prognostic factors, and survival outcomes in patients with blastic plasmacytoid dendritic cell neoplasm: a retrospective study in the Surveillance, Epidemiology, and End Results database. *Eur J Haematol*. 2023;110(6):743-753.